1241675-38-6

Upstream product

• 20776-50-5 2-amino-4-bromobenzoic acid 
• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 
• 101861-53-4 2-(methylcarbonylamino)-4-bromobenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 1464152-27-9 N-(5-(3-(4-cyanophenyl)imidazo[1,2-a]pyridin-6-yl)-2-(morpholine-4-carbonyl)phenyl)acetamide 
• 1464157-65-0 2-acetamido-4-(3-(4-cyanophenyl)imidazo[1,2-a]pyridin-6-yl)benzoic acid 
• 1464157-62-7 methyl 2-acetamido-4-(3-(4-cyanophenyl)imidazo[1,2-a]pyridin-6-yl)benzoate 
• 760989-61-5 methyl 2-acetamido-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 

Relevant academic research and scientific papers

TRICYCLIC PYRIDONES AND PYRIMIDONES

A compound of Formula (I) is provided: (I) where the variables are defined herein.

QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF

This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R4, Rq, o, RA, W and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.

BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases